An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1
- PMID: 27580249
- PMCID: PMC5215501
- DOI: 10.1080/21645515.2016.1221872
An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1
Abstract
This paper describes a single site, open-label Phase I clinical trial evaluating the safety, tolerability and immunogenicity in healthy volunteers of a herpes simplex polynucleotide vaccine that has previously been shown to enhance immunogenicity and protect against lethal herpes simplex virus type 2 (HSV-2) challenge in mice. Five escalating doses of the vaccine, COR-1, were given by intradermal injection to HSV-1 and 2 seronegative healthy individuals. COR-1 was found to be safe and well-tolerated; the only vaccine-related adverse events were mild. While vaccine-induced antibody responses were not detectable, cell-mediated immune responses to HSV-specific peptide groups were identified in 19 of the 20 subjects who completed the study, and local inflammation at the immunisation site was observed. This study indicates COR-1 has potential to be used as a therapeutic vaccine for HSV-2 infection.
Keywords: DNA vaccine; Genital herpes; HSV-2; codon-modification; healthy volunteers; polynucleotide vaccine; ubiquitination.
Figures



Similar articles
-
Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system.Clin Vaccine Immunol. 2008 Nov;15(11):1638-43. doi: 10.1128/CVI.00167-08. Epub 2008 Sep 10. Clin Vaccine Immunol. 2008. PMID: 18784341 Free PMC article. Clinical Trial.
-
Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine.J Infect Dis. 2021 Nov 16;224(9):1509-1519. doi: 10.1093/infdis/jiab139. J Infect Dis. 2021. PMID: 33718970 Free PMC article.
-
Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.J Virol. 2005 Jan;79(1):410-8. doi: 10.1128/JVI.79.1.410-418.2005. J Virol. 2005. PMID: 15596834 Free PMC article.
-
Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.Herpes. 2004 Aug;11 Suppl 3:161A-169A. Herpes. 2004. PMID: 15319086 Review.
-
Evolution of rational vaccine designs for genital herpes immunotherapy.Curr Opin Virol. 2016 Apr;17:80-86. doi: 10.1016/j.coviro.2016.01.021. Epub 2016 Feb 18. Curr Opin Virol. 2016. PMID: 26896782 Review.
Cited by
-
Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial.PLoS One. 2019 Dec 17;14(12):e0226320. doi: 10.1371/journal.pone.0226320. eCollection 2019. PLoS One. 2019. PMID: 31846475 Free PMC article. Clinical Trial.
-
Preventive Vaccination with Mesenchymal Stem Cells Protects Mice from Lethal Infection Caused by Herpes Simplex Virus 1.Mol Biol. 2021;55(3):413-423. doi: 10.1134/S0026893321020242. Epub 2021 Dec 16. Mol Biol. 2021. PMID: 34931092 Free PMC article.
-
DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection.J Immunother. 2017 Feb/Mar;40(2):62-70. doi: 10.1097/CJI.0000000000000156. J Immunother. 2017. PMID: 28166181 Free PMC article.
-
A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC).Cancer Immunol Immunother. 2021 Mar;70(3):743-753. doi: 10.1007/s00262-020-02720-7. Epub 2020 Sep 12. Cancer Immunol Immunother. 2021. PMID: 32918586 Free PMC article. Clinical Trial.
-
Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond.Viruses. 2024 Sep 17;16(9):1476. doi: 10.3390/v16091476. Viruses. 2024. PMID: 39339952 Free PMC article. Review.
References
-
- Ryder N, Jin F, McNulty AM, Grulich AE, Donovan B. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992–2006. Sex Transm Infect 2009; 85:416-9; PMID:19273479; http://dx.doi.org/10.1136/sti.2008.033902 - DOI - PubMed
-
- Haddow LJ, Dave B, Mindel A, McPhie KA, Chung C, Marks C, Dwyer DE. Increase in rates of herpes simplex virus type 1 as a cause of anogenital herpes in western Sydney, Australia, between 1979 and 2003. Sex Transm Infect 2006; 82:255-9; PMID:16731681; http://dx.doi.org/10.1136/sti.2005.018176 - DOI - PMC - PubMed
-
- Tran T, Druce JD, Catton MC, Kelly H, Birch CJ. Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003. Sex Transm Infect 2004; 80:277-9; PMID:15295125; http://dx.doi.org/10.1136/sti.2004.009753 - DOI - PMC - PubMed
-
- Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006; 20:73-83; PMID:16327322; http://dx.doi.org/10.1097/01.aids.0000198081.09337.a7 - DOI - PubMed
-
- Barnabas RV, Celum C. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr HIV Res 2012; 10:228-37; PMID:22384842; http://dx.doi.org/10.2174/157016212800618156 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical